{"id":7760,"date":"2026-01-14T07:30:00","date_gmt":"2026-01-14T07:30:00","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/relhearts-ceo-presents-the-company-and-current-share-issue-recording-now-available\/"},"modified":"2026-01-14T07:30:00","modified_gmt":"2026-01-14T07:30:00","slug":"relhearts-ceo-presents-the-company-and-current-share-issue-recording-now-available","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/relhearts-ceo-presents-the-company-and-current-share-issue-recording-now-available\/","title":{"rendered":"Relheart\u2019s CEO Presents the Company and Current Share Issue \u2013 Recording Now Available"},"content":{"rendered":"
\n

Scandinavian Real Heart AB (publ) announces today, January 14, 2026, that a recording of CEO Ina Laura's company presentation, held in connection with the extraordinary general meeting on December 16, 2025, is now available on the company's YouTube channel.<\/strong><\/p>\n<\/div>\n

\n

In the presentation, CEO Ina Laura Perkins gives an overview of the company's operations, technology platform, and strategic direction going forward. Parts of the presentation also touch on the rights issue that the company has previously communicated, the subscription period for which began yesterday, January 13, 2026. The rights issue closes on January 27.<\/p>\n

Ina Laura also demonstrates today's existing artificial heart systems and highlights their limitations from a patient perspective. She compares these with Realheart's patient-centered solution\u2014a heart designed to mimic the natural blood flow of the human heart and an external patient unit that is quiet, lightweight, and has a long battery life. All this is done to create the best conditions for long-term treatment of patients with severe heart failure.<\/p>\n

As previously announced, the purpose of the issue is to finance the continued development of Realheart's artificial heart Realheart\u00ae TAH and to strengthen the company's financial position ahead of upcoming development and regulatory steps. Full terms and conditions for the issue, including the subscription period, use of issue proceeds, and other details, are set out in previous press releases.<\/p>\n

Read more and subscribe here: https:\/\/realheart.se\/preferential-rights-issue-realheart\/<\/a><\/p>\n

A recording of the presentation* is available on the Company's YouTube channel: https:\/\/youtu.be\/AaaZkgmn4GM<\/a><\/p>\n

* The presentation is in Swedish.<\/em><\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong>
Ina Laura Perkins, CEO
Phone: +46 (0) 70 406 49 21\u00a0
E-mail: inalaura.perkins@realheart.se<\/a>
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

About Us<\/strong>
Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart\u00ae TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se<\/a><\/p>\n<\/div>\n

\n

Attachments<\/strong>
Relheart\u2019s CEO Presents the Company and Current Share Issue \u2013 Recording Now Available<\/a><\/p>\n<\/div>\n